Please confirm you are human
(Sign Up for free to never see this)
← Back to Search
Some data provided by SemanticScholar
DOI: 10.1002/jmri.25661
Identifying Relations Between Imaging Phenotypes And Molecular Subtypes Of Breast Cancer: Model Discovery And External Validation
J. Wu, Xiaoli Sun, J. Wang, Y. Cui, F. Kato, H. Shirato, D. Ikeda, R. Li
Published 2017 · Medicine
Twitter
Facebook
LinkedIn
Email To determine whether dynamic contrast enhancement magnetic resonance imaging (DCE‐MRI) characteristics of the breast tumor and background parenchyma can distinguish molecular subtypes (ie, luminal A/B or basal) of breast cancer.
This paper references
10.1148/radiol.15142698
Breast Cancer: Radiogenomic Biomarker Reveals Associations among Dynamic Contrast-enhanced MR Imaging, Long Noncoding RNA, and Metastasis.
S. Yamamoto (2015)
10.1007/s00330-015-3845-6
Magnetic resonance imaging texture analysis classification of primary breast cancer
S. Waugh (2015)
molecular classes predicts response to neoadjuvant chemotherapy
J Baselga (2010)
10.2214/AJR.11.7824
Radiogenomic analysis of breast cancer using MRI: a preliminary study to define the landscape.
S. Yamamoto (2012)
10.1007/s00330-012-2403-8
Correlations between diffusion-weighted imaging and breast cancer biomarkers
L. Martincich (2012)
10.1109/TMI.2010.2046908
N4ITK: Improved N3 Bias Correction
N. Tustison (2010)
10.1038/35021093
Molecular portraits of human breast tumours
C. Perou (2000)
10.1007/s00330-015-4011-x
Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response
H. Preibsch (2015)
10.1097/MD.0000000000003000
Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging
Ji Soo Choi (2016)
10.1200/JCO.2013.54.1870
Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.
F. Ades (2014)
10.2214/AJR.07.2533
Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy.
J. Hattangadi (2008)
10.1038/modpathol.2010.33
Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy
S. Schnitt (2010)
10.1148/radiol.2015150013
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
N. Hylton (2016)
10.1148/radiol.15142192
Association between Parenchymal Enhancement of the Contralateral Breast in Dynamic Contrast-enhanced MR Imaging and Outcome of Patients with Unilateral Invasive Breast Cancer.
Bas H. M. van der Velden (2015)
10.1111/J.2517-6161.1996.TB02080.X
Regression Shrinkage and Selection via the Lasso
R. Tibshirani (1996)
10.1002/jmri.25119
Breast cancer molecular subtype classifier that incorporates MRI features
E. Sutton (2016)
10.1016/J.YONC.2012.08.009
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
J. Thigpen (2012)
10.1002/jmri.24884
MRI phenotype of breast cancer: Kinetic assessment for molecular subtypes
Eric M Blaschke (2015)
10.1158/1078-0432.CCR-16-2415
Unsupervised Clustering of Quantitative Image Phenotypes Reveals Breast Cancer Subtypes with Distinct Prognoses and Molecular Pathways
J. Wu (2017)
10.1093/annonc/mdr304
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch (2011)
10.1148/radiol.11102156
Background parenchymal enhancement at breast MR imaging and breast cancer risk.
Valencia King (2011)
10.1148/RADIOL.2016152110
MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.
H. Li (2016)
10.1073/pnas.1732912100
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
C. Sotiriou (2003)
10.1093/annonc/mds586
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.
S. Guiu (2012)
10.1148/radiol.13130459
Background parenchymal signal enhancement ratio at preoperative MR imaging: association with subsequent local recurrence in patients with ductal carcinoma in situ after breast conservation surgery.
Sun-Ah Kim (2014)
10.1200/JCO.2008.18.1370
Supervised risk predictor of breast cancer based on intrinsic subtypes.
J. Parker (2009)
10.1148/radiol.2015151169
Radiomics: Images Are More than Pictures, They Are Data
R. Gillies (2016)
10.1016/J.BREASTDIS.2015.10.008
Identification of Intrinsic Imaging Phenotypes for Breast Cancer Tumors: Preliminary Associations with Gene Expression Profiles
K. Shin (2015)
10.1002/jmri.24934
Histogram analysis of apparent diffusion coefficient at 3.0t: Correlation with prognostic factors and subtypes of invasive ductal carcinoma
Eun Jeong Kim (2015)
10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
Index for rating diagnostic tests
W. Youden (1950)
10.1148/radiol.14132641
Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging.
M. Mazurowski (2014)
10.1148/radiol.2015142304
Are Qualitative Assessments of Background Parenchymal Enhancement, Amount of Fibroglandular Tissue on MR Images, and Mammographic Density Associated with Breast Cancer Risk?
Brian N Dontchos (2015)
10.1371/journal.pone.0143308
Identifying Triple-Negative Breast Cancer Using Background Parenchymal Enhancement Heterogeneity on Dynamic Contrast-Enhanced MRI: A Pilot Radiomics Study
J. Wang (2015)
10.1002/jmri.25279
Intratumor partitioning and texture analysis of dynamic contrast‐enhanced (DCE)‐MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy
J. Wu (2016)
10.1148/radiol.14121031
Computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced MR images: a feasibility study.
S. Agner (2014)
10.1016/j.mric.2013.02.005
Updates and revisions to the BI-RADS magnetic resonance imaging lexicon.
Sonya D Edwards (2013)
10.1002/CNCR.25798
Erratum: Immunohistochemical Surrogate Markers of Breast Cancer Molecular Classes Predicts Response to Neoadjuvant Chemotherapy
R. Bhargava (2011)
10.1200/JCO.2006.07.1522
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
S. Loi (2007)
10.1148/radiol.12110748
Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
N. Hylton (2012)
10.1080/07357900701784238
Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer
J. Peppercorn (2008)
Index for rating diagnostic tests. Cancer 1950;3:32–35
WJ Youden (1950)
10.1002/jmri.24890
Breast cancer subtype intertumor heterogeneity: MRI‐based features predict results of a genomic assay
E. Sutton (2015)
This paper is referenced by
10.1007/s11307-019-01383-w
Radiomic Signatures Derived from Diffusion-Weighted Imaging for the Assessment of Breast Cancer Receptor Status and Molecular Subtypes
D. Leithner (2019)
10.1007/978-3-319-94878-2
Artificial Intelligence in Medical Imaging
E. Ranschaert (2019)
10.1007/s11517-017-1770-3
Automated breast tumor detection and segmentation with a novel computational framework of whole ultrasound images
L. Liu (2017)
10.1016/j.acra.2018.01.023
Breast Cancer Molecular Subtype Prediction by Mammographic Radiomic Features.
W. Ma (2019)
10.1007/s00330-019-06084-0
Can peritumoral radiomics increase the efficiency of the prediction for lymph node metastasis in clinical stage T1 lung adenocarcinoma on CT?
X. Wang (2019)
10.1038/s41416-018-0185-8
A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features
Ashirbani Saha (2018)
10.1186/s13244-020-00895-2
Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer
Paula Martín-González (2020)
10.1002/jmri.26762
Background parenchymal enhancement on breast MRI: A comprehensive review
G. Liao (2019)
10.3389/fonc.2019.01062
Predictive Power of a Radiomic Signature Based on 18F-FDG PET/CT Images for EGFR Mutational Status in NSCLC
X. Li (2019)
10.1148/radiol.2017162823
Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer.
J. Wu (2017)
10.1016/j.jconrel.2017.10.036
Targeted cancer therapy through antibody fragments‐decorated nanomedicines
A. Alibakhshi (2017)
10.1002/mp.12925
Breast cancer MRI radiomics: An overview of algorithmic features and impact of inter‐reader variability in annotating tumors
Ashirbani Saha (2018)
10.1001/jamanetworkopen.2019.2561
Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)–Positive Breast Cancer
Nathaniel Braman (2019)
10.1007/s00330-018-5891-3
Radiomic analysis of imaging heterogeneity in tumours and the surrounding parenchyma based on unsupervised decomposition of DCE-MRI for predicting molecular subtypes of breast cancer
Ming Fan (2018)
10.1186/s13058-019-1187-z
Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results
D. Leithner (2019)
10.1016/J.EJRAD.2019.02.018
Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
G. DiLorenzo (2019)
10.1186/s13058-018-1039-2
Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer
J. Wu (2018)
10.1002/jmri.26878
Artificial intelligence in the interpretation of breast cancer on MRI
D. Sheth (2019)
10.1007/s10334-020-00892-y
A radiomics pipeline dedicated to Breast MRI: validation on a multi-scanner phantom study
Marie-Judith Saint Martin (2020)
10.1007/s00432-018-2595-7
A study of association of Oncotype DX recurrence score with DCE-MRI characteristics using multivariate machine learning models
Ashirbani Saha (2018)
10.1117/12.2295471
Breast cancer molecular subtype classification using deep features: preliminary results
Z. Zhu (2018)
10.1007/s11517-020-02232-7
A comprehensive hierarchical classification based on multi-features of breast DCE-MRI for cancer diagnosis
H. Liu (2020)
10.1002/jmri.26556
Role of texture analysis in breast MRI as a cancer biomarker: A review
Rhea D Chitalia (2019)
10.1016/j.compbiomed.2019.04.018
Deep Learning for identifying radiogenomic associations in breast cancer
Z. Zhu (2019)
10.1186/s12885-020-07053-3
Diagnosis of triple negative breast cancer based on radiomics signatures extracted from preoperative contrast-enhanced chest computed tomography
Q. Feng (2020)
10.35711/aimi.v1.i1.6
Breast dynamic contrast-enhanced-magnetic resonance imaging and radiomics: State of art
Alessia Angela Maria Orlando (2020)
10.1093/jrr/rrx102
Radiomics and radiogenomics for precision radiotherapy
J. Wu (2018)
10.1016/j.acra.2019.09.012
Breast Cancer Radiogenomics: Current Status and Future Directions.
L. Grimm (2020)
10.1002/jmri.26852
Machine learning in breast MRI
B. Reig (2019)
10.1109/JPROC.2019.2950187
Comparison of Breast MRI Tumor Classification Using Human-Engineered Radiomics, Transfer Learning From Deep Convolutional Neural Networks, and Fusion Method
H. M. Whitney (2020)
10.1155/2019/6978650
Molecular Subtypes Recognition of Breast Cancer in Dynamic Contrast-Enhanced Breast Magnetic Resonance Imaging Phenotypes from Radiomics Data
Wei Li (2019)
10.1016/j.clinimag.2018.08.011
MR imaging features and tumor biomarkers of screen-detected and non-screen detected breast cancers: preliminary results of a comparative study.
E. Panourgias (2018)
See more
Some data provided by SemanticScholar